You are reading 1 of 2 free-access articles allowed for 30 days
CancerLinq is an initiative which connects and analyses “real-world” cancer data from almost any electronic health record source.
At the recent ASCO 2016 annual meeting in Chicago, US, the organisation’s President Dr Julie Vose stressed the importance of CancerLinq, given that it allows for important data to be gathered from the 97 per cent of cancer patients who do not take part in clinical trials.
According to data released at the meeting, 58 practices have signed up to the initiative. So far, 1,000 patients are involved and 750,000 patient records have been collected.
CancerLinq CEO Mr Kevin Fitzpatrick told MI that there are plans to roll the project out to countries outside the US.
Mr Fitzpatrick said that discussions have already taken place for CancerLinq to be established in sites in Germany and the Netherlands.
“There are also centres in Latin America and in Singapore that are under discussion,” according to Mr Fitzpatrick.
“What is nice is that so many major academic medical centres in Europe run on the [software system] SAP stack. The technical integration should not be difficult. The more difficult issue is understanding the privacy regulations in those different countries. But I am sure we can overcome that. It is mainly about having a champion at a participating institution who sees this as an important component of their care environment.”
During the meeting, ASCO also presented details of its precision medicine trial TAPUR. The clinical trial, which is the first to be conducted by the Society, is intended to evaluate new uses for targeted therapies outside of FDA-approved indications.
To participate in the study, patients must have a genomic variant that can be matched to a study drug. The study also hopes to learn from real-world prescribing practices, educate oncologists on how to use genomically-targeted drugs, and catalogue oncologists’ choice of genomic profiling tests.
It was revealed that 37 clinical sites are enrolling patients for the trial in the US and there are 17 marketed therapies available at no cost to the 47 patients who have consented to participate to date.